She has contributed to the initiation of numerous Investigational New Drug applications, and to multiple drug and biologic marketing applications in a spectrum of clinical indications. Spellman recently served as Chief Medical Officer at Castle Creek Biosciences, and prior to that at Menlo Therapeutics.
Spellman will be working with the Company as a medical advisor and clinical development consultant. Mary Spellman, a board-certified dermatologist. Supporting the leadership team through the clinical development process is Dr. Mahoney led numerous cross-functional pharmaceutical project teams through all stages of development, from product concept through commercialization. She also held positions in project management, product development and commercial supply chain at Sanofi-Aventis. Ms.
Mahoney was Vice President of Scientific Operations and Business Development at Cutanea Life Sciences, Inc. Mahoney is a pharmaceutical development executive with more than 25 years of experience in the industry. He also has prior experience in senior financial and investor relations roles.Ī key part of this new leadership team includes the appointment of Linda Mahoney as Vice President of Project Development, where she will lead the coordination of a multifunctional team to advance INTASYL compounds through the clinical development process. Bitterman brings 25 years of executive leadership experience in the pharmaceutical and biologic life science industry. Appointed Executive Chairman in September of this year, he assumed the duties leading all aspects of the Company's operations. The newly expanded leadership team is led by industry veteran Robert Bitterman, a member of the board of directors since 2012. The new leadership team will join the current executive team to move the Company forward as it evolves its proprietary platform, INTASYL, from discovery to development. The continuing enrollment in its first-in-human clinical study of PH-762 for advanced melanoma, along with recent positive data from four of its preclinical studies, has attracted new and industry-experienced executives to the Company. INTASYL is the only self-delivering RNAi technology focused on immuno-oncology therapeutics. Phio is a clinical stage biotechnology company whose proprietary INTASYL™ technology makes immune cells more effective in killing tumor cells. (Nasdaq: PHIO), today announced new appointments to the leadership team, reported its financial results for the quarter ended Septemand provided a business update. 10, 2022 /PRNewswire/ - Phio Pharmaceuticals Corp. New executive team leading development of Phio's RNAi compounds and proprietary INTASYL™ platformĬontinuing enrollment in its Phase 1b study of PH-762 for the treatment of advanced melanomaĪdditional studies demonstrate INTASYL's activity against multiple protein targets including PD-1, BRD4, CTLA4, TIGIT and CTGF
0 kommentar(er)
